Switching Study Concludes That Transition From Humira To Samsung Bioepis's Adalimumab Biosimilar Is Safe and Effective | Goodwin
Results of the PROPER study, an interim analysis assessing the safety and efficacy of switching from Abbvie’s Humira to Samsung Bioepsis’s biosimilar adalimumab product, SB5, were...